LSV Asset Management Buys 471,319 Shares of GoodRx Holdings, Inc. $GDRX

LSV Asset Management raised its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 20.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,825,900 shares of the company’s stock after purchasing an additional 471,319 shares during the quarter. LSV Asset Management’s holdings in GoodRx were worth $7,658,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in GoodRx by 7.3% in the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after purchasing an additional 624,182 shares in the last quarter. Ameriprise Financial Inc. grew its stake in GoodRx by 4.0% in the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after purchasing an additional 184,734 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new position in GoodRx in the fourth quarter valued at approximately $4,812,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of GoodRx by 10,242.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after buying an additional 1,488,137 shares during the last quarter. Finally, Pathway Capital Management LP lifted its position in shares of GoodRx by 69.0% in the third quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock valued at $4,171,000 after buying an additional 402,721 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GDRX has been the subject of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $3.50 price objective on shares of GoodRx in a research report on Friday, May 8th. Leerink Partners reaffirmed an “outperform” rating and issued a $3.00 price objective on shares of GoodRx in a research report on Thursday, February 26th. TD Cowen raised their price objective on GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Mizuho cut their price objective on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Friday, February 27th. Finally, Wells Fargo & Company cut their price objective on GoodRx from $7.00 to $3.50 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, GoodRx has an average rating of “Hold” and an average price target of $3.81.

GoodRx Stock Performance

GDRX opened at $2.78 on Wednesday. GoodRx Holdings, Inc. has a 12-month low of $1.77 and a 12-month high of $5.81. The stock has a market cap of $952.34 million, a price-to-earnings ratio of 46.34, a PEG ratio of 1.69 and a beta of 1.54. The business has a 50 day moving average of $2.32 and a 200-day moving average of $2.49. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $194.01 million during the quarter, compared to analysts’ expectations of $185.40 million. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period last year, the firm posted $0.09 EPS. On average, equities research analysts expect that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.